Wire · operational-macro
Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 October 2026 · Fusion42 review
The FDA has approved Opus Genetics' phentolamine ophthalmic solution 0.75% for treating presbyopia in adults, supported by positive Phase 3 trial results. This approval expands the drug's indications and triggers a milestone payment to Opus Genetics under a commercialization agreement with Viatris in the U.S.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
You can now enter the U.S. presbyopia treatment market with a newly FDA-approved eye drop that avoids muscle interference, opening commercialisation paths beyond traditional lenses. Your development or marketing plans should factor in this new non-invasive drug option and the established Viatris partnership.
◆ Coverage
1 source · 16 Oct 2026
◆ Related on Wire
◆ Topics